Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Oportuzumab monatox
Другие языки:

Oportuzumab monatox

Подписчиков: 0, рейтинг: 0
Oportuzumab monatox
Monoclonal antibody
Type Single-chain variable fragment
Source Humanized
Target EpCAM
Clinical data
Other names oportuzumab monatox-qqrs
ATC code
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C3072H4723N877O952S12
Molar mass 69558.48 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Oportuzumab monatox is an experimental anti-cancer medication. Chemically, oportuzumab is a single chain variable fragment of a monoclonal antibody which binds to epithelial cell adhesion molecule (EpCAM, the tumor-associated calcium signal transducer 1). Oportuzumab is fused with Pseudomonas aeruginosa exotoxin A (which is reflected by the monatox in the medication's name).

The drug was developed by Canadian-based Viventia Bio Inc. The company was acquired by Cambridge(MA)-based Eleven Biotherapeutics in 2016, which then changed its name to Sesen Bio. In 2019 Sesen Bio reported updated, preliminary primary and secondary endpoint data from the company's Phase 3 VISTA trial further supporting the strong benefit-risk profile of Vicineum for the potential treatment of patients with high-risk, bacillus Calmette-Guérin(BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC). The Company applied for approval of Vicineum by the United States Food and Drug Administration and the European Medicines Agency.

Vol 24, No 18S (June 20 Supplement), 2006: 4580



Новое сообщение